TRIAZOLAM (HALCION) is a triazolobenzodiazepine sedative-hypnotic that has received extensive negative publicity in the lay press since it was first marketed in 1977 in Belgium and the Netherlands. Anecdotal reports of adverse effects beyond those of other benzodiazepines appeared beginning in 1979. 1 Two recent events have once again brought triazolam under intense public scrutiny.P In 1988, a Utah woman killed her mother while reportedly under the influence of triazolam. Because she was judged involuntarily intoxicated at the time of the killing, the case never came to trial. In 1989, she sued Upjohn for $21 million for marketing a "defective drug." Upjohn recently settled out of court for an undisclosed sum.' Some may consider this a tacit admission of guilt. However, it could also be argued that Upjohn was merely trying to avoid a trial that could be sensationalized by the lay press, particularly since the weight of the scientific evidence supports triazolam's safety and efficacy in the treatment of insomnia.
In the United Kingdom (UK), Halcion was removed from the market on October 2, 1991, because of new information regarding the drug's safety.' The Committee on Safety of Medicines, the UK's equivalent of the Food and Drug Administration (FDA), alleged that Upjohn falsified information on a study that involved approximately 50 prisoners who were given triazolam 1.0 mg/d as part of a multicenter trial conducted in the 1970s involving approximately 4000 subjects. This is a triazolam dosage that is now recognized as unsafe. The 50 subjects had a higher rate of amnesia and dysphoria than originally reported. Upjohn officials assert that the mistake resulted from a transcription error that occurred during the reporting process. During a lawsuit, Upjohn's lawyers discovered the error and reported the revised figures to all the countries in which this study was required for the licensing of the drug. When contacted, Upjohn officials had not yet prepared an official statement regarding the incident.
The triazolam controversy dates back to 1979, when van der Kroef published a report detailing a wide range of serious adverse effects seen in 25 patients, including amnesia, psychosis, aggression, paralysis, catatonia, and with- drawal anxiety.' Although many of these adverse reactions have never been observed under controlled conditions, this report led to intense media scrutiny that resulted in triazolam's removal from the Dutch market in 1979, despite widespread criticism from the scientific community! Since that time, it has become apparent that triazolam does, in fact, produce significant adverse effects. These effects include delirium in psychiatric patients and the elderly, withdrawal reactions, and anterograde amnesia.1 Of these, the delirium and withdrawal reactions are potential adverse effects that should be anticipated with all benzodiazepines in predisposed patient populations. Critics argue that these effects simply occur more often with triazolam.v' Others suggest that these are normal, dose-related adverse effects," Whatever the explanation, the incidence of delirium and withdrawal can be easily reduced simply by restricting triazolam use to appropriate situations at appropriate doses. Too often, hypnotics are misused at ever-increasing doses as the primary treatment of chronic insomnia. The fact that their efficacy is often exhausted within three weeks of chronic use is frequently forgotten by clinicians. The primary treatment of chronic insomnia is nonpharmacologic. Measures such as sleep restriction therapy, standardization of the sleep schedule, optimization of the sleep environment, increased exercise, stress management, and elimination of sleep-altering drugs (e.g., caffeine, alcohol, tobacco, sympathomirnetics) are all treatments that carry no adverse effects, unlike their pharmacologic alternatives. The role of drugs is limited to short-term adjunctive use. This is especially true for triazolam doses~0.5 mg where withdrawal insomnia has been observed after a single dose,"
Benzodiazepine-induced anterograde amnesia (loss of memory for events following use of the drug) was considered serious enough for the FDA to require revised labeling of triazolam, temazepam, and flurazepam. The package insert now warns patients and physicians that "cases of traveler's amnesia have been reported by individuals who have taken Halcion to induce sleep while traveling, such as during an airplane flight. In some of these cases, insufficient time was allowed for the sleep period prior to awakening and before beginning activity. Also, the concomitant use of alcohol may have been a factor in some cases."IO The woman who killed her mother while receiving triazolam reports that she has little memory of the event.' Furthermore, two studies suggest that triazolam may produce anterograde amnesia at typical therapeutic doses at a higher rate than both temazepamt-P and flurazeparn." Sharf et al. compared single doses of triazolam 0.5 mg, temazepam 30 mg, and placebo in healthy volunteers and in people with chronic insomnia in a double-blind, parallel-group study. In both the healthy adults and in those with insomnia, delayed recall was significantly impaired 13.5 hours after the triazolam dose compared with placebo. However, there was no difference between temazepam and placebo. However, the triazolam group had significantly more memory impairment at 24 hours compared with placebo than either temazepam or flurazepam."
In another recent study of the amnestic effects of triazolam, Bixler et al. randomized 18 people with chronic insomnia to receive triazolam 0.5 mg/d, temazepam 30 mg/d, or placebo for a 12-day study. Of the 12 subjects who received active medication, placebo was administered from days 1 through 4 and on day 12. Half of these patients received active medication on days 5-8 and 11; the other 6 received drug on days 5-7, 9, and 10. The drugs were administered in this fashion to maintain the investigators' blindness while allowing analysis of the effects of intermittent administration. Five of the 6 triazolam-treated patients reported at least one episode of memory impairment or amnesia on days following drug administration, with a total of 12 episodes for 30 subject-drug nights (a 40 percent rate). Similar results were not seen in the placebo or temazepam groups. Objective tests of memory function also demonstrated a significant effect for triazolam compared with placebo and temazepam 3 days following drug withdrawal.' Interpretation of these data is difficult as 8 of the 12 episodes of memory impairment occurred in 2 of the 6 triazolam subjects. The possibility that these patients are outliers must be considered. Furthermore, the effect of age on triazolam clearance in these 2 patients could not be assessed as their age was not stated. The combination of poor hepatic function in older patients and a relatively high dose of triazolam (0.5 mg) may have skewed the results of this study.
Other studies, however, contradict these findings, suggesting that longer-acting benzodiazepines such as flurazepam produce greater amnestic effects than triazolarn.Pv' Juhlet al. tested the recent memory of three groups of hospitalized patients who received either triazolam (n=49, median 0.25 mg), flurazepam (n=54, median 30 mg), or no hypnotic (n=51). They found that ten flurazepam, two triazolam, and two control patients failed a recent memory three-hour recall test the morning after administration of the drug." Roehrs et al. found that repeated administration of flurazepam 30 mg increased the benzodiazepine-induced amnestic effect, which was not the case with the shorter-acting benzodiazepines (lorazepam 4 mg and triazolam 0.25 and 0.5 mg). However, all of the drugs produced more memory dysfunction than placebo."
The available data suggest that the likelihood of amnesia associated with triazolam is similar to that seen with other benzodiazepines. The risk of triazolam-induced amnesia begins to increase at or above doses of 0.25 mg. As a result, triazolam should be started and maintained at the lowest possible dosage, starting at 0.125 mg/d and preferably not rising above 0.25 mg/d in most patients. However, triazolam's critics contend that the drug is not effective as a hypnotic at dosages this low,? Nevertheless, studies documenting the short-term efficacy oftriazolam in dosages of 0.125 mg/d in elderlyl5,16 and 0.25 mg/d in nonelderly adults l7 ,18 are widely available.
Drug therapy for insomnia is not without risks. Triazolam has been reported to have generated between 3 and 45 times as many reports of adverse reactions in the FDA's spontaneous reporting system compared with temazepam and flurazepam.F' Unfortunately, a voluntary reporting system such as this, while necessary, cannot be expected to generate even remotely reliable data. This is especially true when one considers the amount of bias entered into the system by triazolam's history of unfavorable press. Therefore, the clinician must rely upon controlled scientific data to make a sound therapeutic decision regarding triazolam's use. The available data support triazolam's efficacy and safety as a hypnotic. The lowest effective doses of triazolam for inducing and maintaining sleep are 0.125 mg in elderly patients l 5 ,16 and 0.25 mg in middle-aged patients. 17 ,18 There is one report that suggests that triazolam's threshold dose for memory dysfunction is 0.25 mg;12 the remainder suggest a threshold dose of 0.5 mg. 7 ,1l Thus, patients should be prescribed an initial triazolam dose of 0.125 mg to be titrated upward if necessary. All patients receiving triazolam should be warned of possible memory deficits, particularly if they require a dose of 0.25 mg. Patients also should be informed that memory problems are not limited to triazolam but are a possibility for all of the benzodiazepine medications.
